ClinicalTrials.gg
CompletedNCT02325219Updated May 22, 2020Results posted

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

A Phase 3 interventional study of CNTO 1959 50 mg and CTNO 1959 100 mg in Psoriasis, sponsored by Janssen Pharmaceutical K.K.. Completed at 27 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-05-22.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing guselkumab in Psoriasis — 8 open to participants now, 9 under way, 1 of them phase 3. guselkumab · Psoriasis.

Enrollment
12th of 29
192 · median 120
Started
2014
with 1 other
Phase 3
12 of 29
none open now
Registered
5th of 29
by date
Lead sponsor
5 of 29
Janssen Pharmaceutical K.K.

Among the 29 studies testing guselkumab in Psoriasis, this one is the 12th largest by enrollment, is one of 2 that started in 2014, is one of 12 in phase 3, and was the 5th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

8 of the 29 studies testing guselkumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing guselkumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches).

Read the detailed description

A Phase 3, multicenter (when more than one hospital or medical school team work on a medical research study), randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know about the study treatment), placebo-controlled (a pretend treatment [with no drug in it] that is compared in a clinical trial with a drug to test if the drug has a real effect) study of CNTO 1959 (Guselkumab) in the treatment of participants with moderate to severe plaque-type psoriasis. Participants will receive either treatment of CNTO 1959 (guselkumab) 50 milligram (mg) or 100 mg or Placebo 50 mg or 100 mg. Participants will primarily be assessed for Investigator's Global Assessment (IGA) Score and Psoriasis Area and Severity Index (PASI). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • CNTO 1959
  • Guselkumab
  • Placebo
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of plaque-type psoriasis with or without psoriatic arthritis for at least 6 months before Screening
  • Have a PASI greater than or equal to (>=) 12 at Screening and at Baseline
  • Have an IGA >= 3 at Screening and at Baseline
  • Have an involved body surface area (BSA) >=10 percent (%) at Screening and at Baseline
  • Be a candidate for phototherapy or systemic treatment for psoriasis (either naive or history of previous treatment)

Exclusion criteria

Exclusion Criteria:

  • Has a history of or current signs or symptoms of severe, progressive, or uncontrolled cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, psychiatric, or metabolic disturbances
  • Has unstable cardiovascular disease, defined as a recent clinical deterioration (example, unstable angina, atrial fibrillation) in the last 3 months or a cardiac hospitalization within the last 3 months before Screening
  • Currently has a or has a history of malignancy within 5 years before screening (with the exception of a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study drug administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before Screening
  • Has a history of lymphoproliferative disease, including lymphoma; a history of monoclonal gammopathy of undetermined significance (MGUS); or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy and/or splenomegaly
  • Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (eg, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection (mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
192 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive subcutaneous injection of CNTO 1959 50 milligram (mg) and placebo 100 mg at Week 0, 4 and then every 8 weeks thereafter.

    Drug: CNTO 1959 50 mg · Drug: Placebo 100 mg

  • Experimental
    Group 2

    Participants will receive subcutaneous injection of CNTO 1959 100 milligram (mg) and placebo 50 mg at Week 0, 4 and then every 8 weeks thereafter.

    Drug: CTNO 1959 100 mg · Drug: Placebo 50 mg

  • Experimental
    Group 3

    Participants will receive subcutaneous injection of placebo 50 mg and 100 mg at Weeks 0, 4 and 12. At Week 16, participants will be randomized in sub-group 3a to receive either CNTO1959 50 mg and placebo 100 mg at Week 16, 20 and then every 8 weeks thereafter or sub-group 3b to receive CNTO 1959 100 mg and placebo 50 mg at Week 16, 20 and then every 8 weeks thereafter.

    Drug: CNTO 1959 50 mg · Drug: CTNO 1959 100 mg · Drug: Placebo 50 mg · Drug: Placebo 100 mg

Interventions

  • Participants will receive subcutaneous injection of CNTO 1959 50 mg.

    Also known as: Guselkumab

  • Participants will receive subcutaneous injection of CNTO 1959 100 mg.

    Also known as: Guselkumab

  • DrugPlacebo 50 mg

    Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.

  • DrugPlacebo 100 mg

    Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Week 16

  2. Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Who Achieved PASI 75 Response at Week 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

    Time frame: Week 16

  2. Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Baseline and Week 16

  3. Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 2, 4, 8, 12, and 16

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 2, 4, 8, 12, and 16

  4. Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

    The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

  5. Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 2, 4, 8, 12, and 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.

    Time frame: Weeks 2, 4, 8, 12, and 16

  6. Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.

    Time frame: Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

  7. Percent Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16

  8. Percent Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Baseline and Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52

  9. Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Baseline and Weeks 2, 4, 8, 12, 16

  10. Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52

    The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

    Time frame: Baseline and Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52

  11. Change From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48

    BSA as physical measure to define disease severity is to determine how much of the Body Surface Area (BSA) is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

    Time frame: Baseline and Week 48

  12. Change From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16

    NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

    Time frame: Baseline and Week 16

  13. Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52

    NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

    Time frame: Baseline and Weeks 28, 36, 48, 52

  14. Percent Change From Baseline in NAPSI Score at Week 16

    NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

    Time frame: Baseline and Week 16

  15. Percent Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52

    NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

    Time frame: Baseline and Weeks 28, 36, 48, 52

  16. Percentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 16

    The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

    Time frame: Week 16

  17. Percentage of Participants With an Ss-IGA Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Weeks 28, 48 and 52

    The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

    Time frame: Week 28, 48 and 52

  18. Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 16

    The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

    Time frame: Week 16

  19. Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 28, 48 and 52

    The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

    Time frame: Week 28, 48 and 52

  20. Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 8 and 16

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Weeks 8 and 16

  21. Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 28, 36, 48, and 52

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Weeks 28, 36, 48, and 52

  22. Change From Baseline in the DLQI Total Score at Week 8

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Baseline and Weeks 8

  23. Change From Baseline in the DLQI Total Score at Weeks 28, 36, 48, 52

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Baseline and Weeks 28, 36, 48, 52

  24. Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 8 and 16

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Weeks 8 and 16

  25. Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 28, 36, 48, and 52

    The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

    Time frame: Weeks 28, 36, 48, and 52

  26. Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 16

    The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline and Week 16

  27. Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Weeks 28 and 48

    The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Baseline and Weeks 28, 48

  28. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 16

    The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).

    Time frame: Baseline and Week 16

  29. Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Weeks 28, 48

    The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).

    Time frame: Baseline and Weeks 28, 48

  30. Change From Baseline in the Physical and Mental Component Summary (PCS and MCS) Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Week 16

    SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.

    Time frame: Baseline and Week 16

  31. Change From Baseline in the PCS and MCS Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Weeks 28 and 48

    SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.

    Time frame: Baseline and Weeks 28, 48

  32. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Week 16

    Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Week 16 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

    Time frame: Baseline and Week 16

  33. Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Weeks 28 and 48

    Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Weeks 28 and 48 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

    Time frame: Baseline and Weeks 28, 48

  34. Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 Responses at Weeks 4, 8, and 16

    ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

    Time frame: Weeks 4, 8, and 16

  35. Percentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 28, 36, 48, and 52

    ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

    Time frame: Weeks 28, 36, 48, and 52

  36. Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16

    Percent change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.

    Time frame: Weeks 4, 8, and 16

  37. Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52

    Percent change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.

    Time frame: Weeks 28, 36, 48, and 52

  38. Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16

    Change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.

    Time frame: Baseline and Weeks 4, 8, 16

  39. Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52

    Change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.

    Time frame: Baseline and Weeks 28, 36, 48, 52

  40. Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 4, 8, 16

    Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 4, 8 and 16 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 millimeter (mm) (no pain) to 100 mm (the worst pain imaginable).

    Time frame: Baseline and Weeks 4, 8, 16

  41. Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 28, 36, 48, 52

    Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 28, 36, 48 and 52 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 mm (no pain) to 100 mm (the worst pain imaginable).

    Time frame: Baseline and Weeks 28, 36, 48, 52

  42. Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 4, 8, 16

    The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 centimeter \[cm\]) to "very poor" (10 cm).

    Time frame: Baseline and Weeks 4, 8, 16

  43. Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 28, 36, 48, and 52

    The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 cm) to "very poor" (10 cm).

    Time frame: Baseline and Weeks 28, 36, 48, 52

  44. Percentage of Participants Who Achieved Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Weeks 4, 8 and 16

    HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).

    Time frame: Weeks 4, 8, and 16

  45. Percentage of Participants Who Achieved HAQ-DI Response at Weeks 28, 36, 48, 52

    HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).

    Time frame: Weeks 28, 36, 48, 52

07

Results

Posted May 14, 2020

Participant flow

Controlled Period (Week 0 - 16)
Participant flow — Controlled Period (Week 0 - 16)
MilestonePlacebo (Controlled Period [CP])Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Started64656300
Completed52636200
Not completed122100
Withdrew: Adverse event61000
Withdrew: Withdrawal by subject61000
Withdrew: Other00100
After Controlled Period (Week 16 - 52)
Participant flow — After Controlled Period (Week 16 - 52)
MilestonePlacebo (Controlled Period [CP])Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Started063622626
Completed060622625
Not completed03001
Withdrew: Adverse event00001
Withdrew: Withdrawal by subject02000
Withdrew: Pregnancy01000

Outcome measures

PrimaryPercentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Percentage of Participants With an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 167.892.388.9
Statistical analysis
  • Placebo (CP) vs Guselkumab 50 mg (CP) · Fisher Exact · p = <0.001
  • Placebo (CP) vs Guselkumab 100 mg (CP) · Fisher Exact · p = < 0.001
PrimaryPercentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 90 response was defined as at least a 90% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI) 90 Response at Week 16070.869.8
Statistical analysis
  • Placebo (CP) vs Guselkumab 50 mg (CP) · Fisher Exact · p = <0.001
  • Placebo (CP) vs Guselkumab 100 mg (CP) · Fisher Exact · p = < 0.001
SecondaryPercentage of Participants Who Achieved PASI 75 Response at Week 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 75 response was defined as at least a 75% reduction in PASI relative to Baseline.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 75 Response at Week 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Percentage of Participants Who Achieved PASI 75 Response at Week 166.389.284.1
SecondaryChange From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Change From Baseline in the Dermatology Life Quality Index (DLQI) Total Score at Week 16-0.8 ± 5.40-8.3 ± 5.87-8.5 ± 6.95
SecondaryPercentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 2, 4, 8, 12, and 16

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 2, 4, 8, 12, and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 2: IGA 0 responders000
Week 2: IGA 0/1 responders03.19.5
Week 2: IGA 0/1/2 responders10.947.746.0
Week 4: IGA 0 responders01.56.3
Week 4: IGA 0/1 responders1.627.725.4
Week 4: IGA 0/1/2 responders20.381.577.8
Week 8: IGA 0 responders016.920.6
Week 8: IGA 0/1 responders1.676.965.1
Week 8: IGA 0/1/2 responders20.393.893.7
Week 12: IGA 0 responders033.833.3
Week 12: IGA 0/1 responders4.789.284.1
Week 12: IGA 0/1/2 responders25.095.496.8
Week 16: IGA 0 responders044.644.4
Week 16: IGA 0/1 responders7.892.388.9
Week 16: IGA 0/1/2 responders28.196.996.8
SecondaryPercentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participants' psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With an IGA Score of Cleared (0), Cleared (0) or Minimal (1), and Cleared (0) or Minimal (1) or Mild (2) at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 20: IGA 0 responders46.257.13.811.5
Week 20: IGA 0/1 responders89.292.157.746.2
Week 20: IGA 0/1/2 responders96.996.884.688.5
Week 24: IGA 0 responders53.857.115.438.5
Week 24: IGA 0/1 responders90.888.988.580.8
Week 24: IGA 0/1/2 responders98.596.896.2100.0
Week 28: IGA 0 responders53.849.250.046.2
Week 28: IGA 0/1 responders90.888.9100.088.5
Week 28: IGA 0/1/2 responders98.595.2100.0100.0
Week 32: IGA 0 responders47.755.653.850.0
Week 32: IGA 0/1 responders89.290.5100.092.3
Week 32: IGA 0/1/2 responders98.596.8100.0100.0
Week 36: IGA 0 responders44.655.661.546.2
Week 36: IGA 0/1 responders89.290.5100.092.3
Week 36: IGA 0/1/2 responders98.596.8100.0100.0
Week 40: IGA 0 responders49.255.665.457.7
Week 40: IGA 0/1 responders87.792.1100.092.3
Week 40: IGA 0/1/2 responders96.998.4100.0100.0
Week 44: IGA 0 responders55.452.461.557.7
Week 44: IGA 0/1 responders86.288.9100.092.3
Week 44: IGA 0/1/2 responders98.596.8100.0100.0
Week 48: IGA 0 responders50.860.373.157.7
Week 48: IGA 0/1 responders86.287.3100.092.3
Week 48: IGA 0/1/2 responders98.596.8100.0100.0
Week 52: IGA 0 responders53.858.753.850.0
Week 52: IGA 0/1 responders87.790.5100.088.5
Week 52: IGA 0/1/2 responders98.598.4100.0100.0
SecondaryPercentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 2, 4, 8, 12, and 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.

Time frame:
Weeks 2, 4, 8, 12, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 2, 4, 8, 12, and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 2: PASI 50 responders04.617.5
Week 2: PASI 75 responders001.6
Week 2: PASI 90 responders000
Week 2: PASI 100 responders000
Week 4: PASI 50 responders1.649.249.2
Week 4: PASI 75 responders015.417.5
Week 4: PASI 90 responders04.64.8
Week 4: PASI 100 responders01.51.6
Week 8: PASI 50 responders9.487.779.4
Week 8: PASI 75 responders055.450.8
Week 8: PASI 90 responders030.830.2
Week 8: PASI 100 responders07.77.9
Week 12: PASI 50 responders7.890.892.1
Week 12: PASI 75 responders3.178.579.4
Week 12: PASI 90 responders047.738.1
Week 12: PASI 100 responders016.922.2
Week 16: PASI 50 responders14.193.895.2
Week 16: PASI 75 responders6.389.284.1
Week 16: PASI 90 responders070.869.8
Week 16: PASI 100 responders032.327.0
SecondaryPercentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90 percentage (%)-100% involvement), and for erythema, induration and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that could range from 0 (no psoriasis) to 72. PASI 50, 75, 90, and 100 responses were defined as at least a 50%, 75%, 90%, and 100% reduction in PASI relative to Baseline respectively.

Time frame:
Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved PASI 50, PASI 75, PASI 90, and PASI 100 Responses at Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 20: PASI 50 responders95.496.857.765.4
Week 20: PASI 75 responders90.888.946.230.8
Week 20: PASI 90 responders70.871.419.215.4
Week 20: PASI 100 responders33.834.93.80
Week 24: PASI 50 responders98.598.492.384.6
Week 24: PASI 75 responders90.890.580.861.5
Week 24: PASI 90 responders78.576.242.346.2
Week 24: PASI 100 responders41.544.411.523.1
Week 28: PASI 50 responders98.598.4100.092.3
Week 28: PASI 75 responders92.390.588.580.8
Week 28: PASI 90 responders75.477.873.161.5
Week 28: PASI 100 responders44.638.130.834.6
Week 32: PASI 50 responders98.598.4100.096.2
Week 32: PASI 75 responders92.390.592.384.6
Week 32: PASI 90 responders76.976.276.969.2
Week 32: PASI 100 responders41.544.434.638.5
Week 36: PASI 50 responders98.595.2100.096.2
Week 36: PASI 75 responders92.390.596.292.3
Week 36: PASI 90 responders78.576.284.665.4
Week 36: PASI 100 responders36.942.930.842.3
Week 40: PASI 50 responders98.598.4100.096.2
Week 40: PASI 75 responders90.890.5100.092.3
Week 40: PASI 90 responders78.577.896.273.1
Week 40: PASI 100 responders33.844.438.550.0
Week 44: PASI 50 responders98.595.2100.096.2
Week 44: PASI 75 responders90.888.9100.092.3
Week 44: PASI 90 responders80.074.688.573.1
Week 44: PASI 100 responders38.544.442.350.0
Week 48: PASI 50 responders98.596.8100.096.2
Week 48: PASI 75 responders90.893.7100.092.3
Week 48: PASI 90 responders75.477.8100.076.9
Week 48: PASI 100 responders36.949.246.242.3
Week 52: PASI 50 responders98.598.4100.096.2
Week 52: PASI 75 responders92.390.5100.092.3
Week 52: PASI 90 responders75.477.892.373.1
Week 52: PASI 100 responders38.547.638.542.3
SecondaryPercent Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16
Reported as:
Mean · percent change
Percent Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16
percent changePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 20.4 ± 18.5520.1 ± 20.8523.6 ± 23.76
Week 40.0 ± 27.7445.3 ± 26.7244.9 ± 30.80
Week 81.5 ± 32.7374.5 ± 22.3970.3 ± 25.42
Week 120.5 ± 38.2883.7 ± 20.0082.9 ± 18.56
Week 160.2 ± 45.5388.9 ± 17.3488.7 ± 17.77
SecondaryPercent Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Time frame:
Baseline and Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52
Reported as:
Mean · percent change
Percent Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 22, 36, 40, 44, 48, and 52
percent changeGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2089.4 ± 18.2190.6 ± 16.4558.7 ± 33.6751.9 ± 39.06
Week 2491.6 ± 14.5992.1 ± 15.5180.7 ± 24.8778.8 ± 22.44
Week 2891.9 ± 14.0591.4 ± 16.2491.6 ± 10.8185.6 ± 20.60
Week 3292.5 ± 12.3892.0 ± 15.7893.1 ± 8.5989.1 ± 19.66
Week 3692.2 ± 13.4290.5 ± 19.4094.7 ± 6.7691.5 ± 13.84
Week 4092.3 ± 13.8692.1 ± 15.8696.4 ± 3.8792.3 ± 14.08
Week 4491.8 ± 17.3091.1 ± 17.2696.6 ± 4.3992.2 ± 14.28
Week 4891.5 ± 17.2892.1 ± 16.1497.9 ± 2.7391.8 ± 14.21
Week 5291.6 ± 17.1292.5 ± 15.3996.7 ± 4.4591.4 ± 14.02
SecondaryChange From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Time frame:
Baseline and Weeks 2, 4, 8, 12, 16
Reported as:
Mean · units on a scale
Change From Baseline in the PASI Total Score at Weeks 2, 4, 8, 12, 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 20.0 ± 4.44-5.7 ± 7.13-6.3 ± 7.17
Week 4-0.2 ± 7.13-12.1 ± 10.55-12.5 ± 11.00
Week 8-1.0 ± 8.99-19.1 ± 10.62-19.2 ± 11.80
Week 12-0.6 ± 10.62-21.4 ± 11.11-22.4 ± 11.86
Week 16-0.5 ± 12.39-22.6 ± 11.00-23.9 ± 12.27
SecondaryChange From Baseline in the PASI Total Score at Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52

The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed separately for the percentage of the area involved, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement), and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4. The PASI produces a numeric score that can range from 0 (no psoriasis) to 72. A higher score indicates more severe disease.

Time frame:
Baseline and Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · units on a scale
Change From Baseline in the PASI Total Score at Weeks 20, 24, 28, 32, 36, 40, 44, 48, 52
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 20-22.8 ± 11.23-24.3 ± 12.52-18.3 ± 15.46-11.3 ± 10.33
Week 24-23.4 ± 11.16-24.7 ± 12.35-24.2 ± 15.12-18.2 ± 9.56
Week 28-23.6 ± 11.44-24.5 ± 12.56-27.0 ± 14.84-20.1 ± 10.52
Week 32-23.7 ± 11.30-24.7 ± 12.58-27.6 ± 15.02-21.0 ± 11.05
Week 36-23.6 ± 11.38-24.3 ± 12.72-28.0 ± 15.02-21.5 ± 10.37
Week 40-23.7 ± 11.51-24.6 ± 12.29-28.4 ± 14.96-21.7 ± 10.65
Week 44-23.5 ± 11.69-24.3 ± 12.29-28.5 ± 15.04-21.6 ± 10.55
Week 48-23.4 ± 11.59-24.6 ± 12.27-28.7 ± 14.90-21.6 ± 10.78
Week 52-23.5 ± 11.74-24.6 ± 12.11-28.5 ± 15.07-21.5 ± 10.62
SecondaryChange From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48

BSA as physical measure to define disease severity is to determine how much of the Body Surface Area (BSA) is affected by psoriasis. Involved BSA is calculated by using the palm of the participant's hand as equivalent to 1% of the BSA (rule of palm). Psoriasis affected BSA under 5% suggests mild psoriasis, a BSA of 5% to 10% is considered moderate, and an involved BSA of over 10% indicates severe psoriasis.

Time frame:
Baseline and Week 48
Reported as:
Mean · Change in BSA (% points)
Change From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48
Change in BSA (% points)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Change From Baseline in Body Surface Area (BSA) Involvement by Psoriatic Lesions at Week 48-31.7 ± 22.40-34.4 ± 21.19-37.1 ± 22.24-27.7 ± 16.08
SecondaryChange From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16

NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Change From Baseline in Nail Psoriasis Area and Severity Index (NAPSI) Score at Week 16-0.2 ± 1.13-1.2 ± 1.61-1.5 ± 1.78
SecondaryChange From Baseline in NAPSI Score at Weeks 28, 36, 48, 52

NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · units on a scale
Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28-2.2 ± 1.79-2.4 ± 2.34-1.7 ± 1.40-0.7 ± 1.13
Week 36-2.3 ± 2.01-2.7 ± 2.23-2.5 ± 1.77-1.2 ± 1.50
Week 48-2.7 ± 1.91-2.7 ± 2.44-3.3 ± 2.22-1.7 ± 1.75
Week 52-2.8 ± 1.94-2.7 ± 2.20-3.3 ± 2.34-1.4 ± 1.54
SecondaryPercent Change From Baseline in NAPSI Score at Week 16

NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

Time frame:
Baseline and Week 16
Reported as:
Mean · percent change
Percent Change From Baseline in NAPSI Score at Week 16
percent changePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Percent Change From Baseline in NAPSI Score at Week 161.0 ± 59.3831.6 ± 43.5639.1 ± 48.93
SecondaryPercent Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52

NAPSI is an index used for assessing and grading the severity of nail psoriasis. A target nail representing the worst nail psoriasis at baseline is divided into quadrants and is graded for nail matrix psoriasis (pitting, leukonychia, red spots in the lunula, and nail plate crumbling) and nail bed psoriasis (onycholysis, splinter hemorrhages, oil drop discoloration, and nail bed hyperkeratosis), each on a scale of 0 to 4. The sum of these scores is the total NAPSI score. The total NAPSI score equals the sum of scores for all of the finger nails evaluated and ranges from 0 (no psoriasis) to 80 (psoriasis present in all 4 quadrants of all 10 nails).

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · percent change
Percent Change From Baseline in NAPSI Score at Weeks 28, 36, 48, 52
percent changeGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2857.9 ± 42.9961.1 ± 43.1548.7 ± 38.7723.6 ± 49.69
Week 3659.6 ± 46.9567.4 ± 45.4469.9 ± 30.4838.4 ± 40.34
Week 4871.0 ± 37.1168.1 ± 49.0180.2 ± 23.0653.7 ± 42.99
Week 5274.4 ± 35.1175.3 ± 41.3279.2 ± 25.6244.9 ± 53.56
SecondaryPercentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 16

The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Percentage of Participants With a Scalp-specific Investigator's Global Assessment (Ss-IGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Week 1610.574.182.8
SecondaryPercentage of Participants With an Ss-IGA Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Weeks 28, 48 and 52

The percentage of participants with an ss-IGA score of absence of disease (0) or very mild disease (1) and at least a 2-grade improvement from Baseline at Week 16 among participants who had an ss-IGA score of \>= 2 at baseline was evaluated. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

Time frame:
Week 28, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants With an Ss-IGA Score of 0 or 1 and at Least a 2-grade Improvement From Baseline at Weeks 28, 48 and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2886.286.290.570.8
Week 4884.584.585.783.3
Week 5284.586.285.795.8
SecondaryPercentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 16

The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Absence of Disease (0)3.548.363.8
Very Mild Disease (1)8.841.422.4
Mild Disease (2)21.18.68.6
Moderate Disease (3)49.11.75.2
Severe Disease (4)17.500
SecondaryPercentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 28, 48 and 52

The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: Absence of Disease (0), Very Mild Disease (1), Mild Disease (2), Moderate Disease (3), and Severe Disease (4).

Time frame:
Week 28, 48 and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Ss-IGA Scores Among Participants With Baseline Ss-IGA Score >=2 at Week 28, 48 and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: Absence of Disease (0)63.870.766.750.0
Week 28: Very Mild Disease (1)31.022.428.625.0
Week 28: Mild Disease (2)3.43.44.812.5
Week 28: Moderate Disease (3)1.73.4012.5
Week 28: Severe Disease (4)0000
Week 48: Absence of Disease (0)67.275.976.266.7
Week 48: Very Mild Disease (1)25.913.89.520.8
Week 48: Mild Disease (2)5.26.99.512.5
Week 48: Moderate Disease (3)1.73.44.80
Week 48: Severe Disease (4)0000
Week 52: Absence of Disease (0)67.277.666.775.0
Week 52: Very Mild Disease (1)27.610.319.020.8
Week 52: Mild Disease (2)3.410.314.34.2
Week 52: Moderate Disease (3)1.71.700
Week 52: Severe Disease (4)0000
SecondaryPercentage of Participants With a DLQI Score of 0 or 1 at Weeks 8 and 16

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 8 and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 86.643.843.3
Week 166.664.168.3
SecondaryPercentage of Participants With a DLQI Score of 0 or 1 at Weeks 28, 36, 48, and 52

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Weeks 28, 36, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With a DLQI Score of 0 or 1 at Weeks 28, 36, 48, and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2870.375.050.068.0
Week 3679.783.379.268.0
Week 4873.473.362.572.0
Week 5273.476.775.080.0
SecondaryChange From Baseline in the DLQI Total Score at Week 8

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Baseline and Weeks 8
Reported as:
Mean · units on a scale
Change From Baseline in the DLQI Total Score at Week 8
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Change From Baseline in the DLQI Total Score at Week 8-0.4 ± 4.71-7.5 ± 5.28-7.0 ± 6.35
SecondaryChange From Baseline in the DLQI Total Score at Weeks 28, 36, 48, 52

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · units on a scale
Change From Baseline in the DLQI Total Score at Weeks 28, 36, 48, 52
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28-9.0 ± 5.85-8.9 ± 6.95-9.5 ± 7.73-5.5 ± 5.19
Week 36-9.2 ± 6.44-9.2 ± 7.27-10.3 ± 8.01-6.1 ± 5.99
Week 48-9.2 ± 6.20-9.1 ± 7.12-10.1 ± 7.94-6.1 ± 5.82
Week 52-9.2 ± 6.39-9.0 ± 7.28-10.1 ± 7.79-6.5 ± 5.05
SecondaryPercentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 8 and 16

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Weeks 8 and 16
Reported as:
Number · percentage of participants
Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 8 and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 817.261.558.7
Week 1620.367.769.8
SecondaryPercentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 28, 36, 48, and 52

The DLQI is a 10-item questionnaire that measures the impact of skin disease on participant's quality of life. Each question was evaluated on a 4-point scale ranging from 0 (not at all) to 3 (very much); where higher scores indicate more impact on quality of life. The DLQI total score ranges from 0 (not at all) to 30 (very much): 0-1 = no effect at all on the participant's life; 2-6 = small effect on the participant's life; 7-12 = moderate effect on the participant's life; 13-18 = very large effect on the participant's life; 19-30 = extremely large effect on the participant's life. Higher scores indicate more impact on quality of life of participants.

Time frame:
Weeks 28, 36, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants With >=5-point Decrease in the DLQI Total Score From Baseline at Weeks 28, 36, 48, and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2869.273.065.457.7
Week 3672.368.369.257.7
Week 4872.371.469.261.5
Week 5272.371.469.261.5
SecondaryChange From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 16

The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Week 160.05 ± 0.1410.20 ± 0.1990.18 ± 0.210
SecondaryChange From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Weeks 28 and 48

The EQ-5D is designed for self-completion by participants and consists of 2 pages - the EQ-5D descriptive system and the EQ visual analog scale (EQ VAS). The EQ-5D descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and severe problems. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Baseline and Weeks 28, 48
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol-5 Dimensions Questionnaire (EQ-5D): Index Score at Weeks 28 and 48
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 280.20 ± 0.1870.20 ± 0.2210.25 ± 0.1700.14 ± 0.133
Week 480.20 ± 0.1980.21 ± 0.2280.28 ± 0.1520.15 ± 0.140
SecondaryChange From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 16

The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Week 162.45 ± 22.44021.20 ± 23.54218.43 ± 26.206
SecondaryChange From Baseline in EQ-5D Visual Analogue Scale (VAS) at Weeks 28, 48

The EQ visual analog scale (EQ VAS) is the part of EQ-5D scale. The EQ VAS records the respondent's self-rated health on a vertical, visual analog scale where the endpoints are labeled 'Best imaginable health state' (score of 100) and 'Worst imaginable health state' (score of 0).

Time frame:
Baseline and Weeks 28, 48
Reported as:
Mean · units on a scale
Change From Baseline in EQ-5D Visual Analogue Scale (VAS) at Weeks 28, 48
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2822.94 ± 24.75920.87 ± 26.46520.73 ± 20.09511.62 ± 26.831
Week 4820.88 ± 29.64721.70 ± 26.57720.38 ± 22.0947.00 ± 29.490
SecondaryChange From Baseline in the Physical and Mental Component Summary (PCS and MCS) Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Week 16

SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: physical component summary (PCS) and mental component summary (MCS). The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in the Physical and Mental Component Summary (PCS and MCS) Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
PCS0.3 ± 9.907.4 ± 15.657.3 ± 14.40
MCS1.3 ± 8.214.0 ± 7.225.3 ± 9.63
SecondaryChange From Baseline in the PCS and MCS Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Weeks 28 and 48

SF-36 V2 is a generic 36-item questionnaire measuring health-related quality of life (HRQL) covering 2 summary measures: PCS and MCS. The SF-36 consists of 8 subscales (physical function, role limitations due to physical problems, pain, general health perception, vitality, social function, role limitations due to emotional problems, and mental health). Participants self-report on items in a subscale that have between 2-6 choices per item using Likert-type responses (e.g. none of the time, some of the time, etc.). Summations of item scores of the same subscale give the subscale scores, which are transformed into a range from 0 to 100; zero= worst HRQL, 100=best HRQL. Higher scores indicate better health status.

Time frame:
Baseline and Weeks 28, 48
Reported as:
Mean · units on a scale
Change From Baseline in the PCS and MCS Scores of 36- Item Short Form Health Assessment Questionnaire (SF-36) at Weeks 28 and 48
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: PCS7.7 ± 13.718.9 ± 14.836.4 ± 10.205.4 ± 9.80
Week 48: PCS8.2 ± 14.228.4 ± 15.168.8 ± 12.134.4 ± 7.60
Week 28: MCS5.9 ± 9.624.6 ± 10.306.5 ± 6.914.9 ± 9.83
Week 48: MCS5.7 ± 9.045.6 ± 9.324.5 ± 9.925.0 ± 11.00
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Week 16

Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Week 16 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Week 16
units on a scalePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Absenteeism0.9 ± 14.96-2.4 ± 8.14-1.9 ± 8.18
Activity Impairment-7.7 ± 24.09-30.9 ± 31.95-33.8 ± 33.91
Presenteeism-7.2 ± 22.62-22.0 ± 34.06-23.7 ± 30.92
Work Productivity Loss-7.6 ± 23.24-23.0 ± 34.38-24.1 ± 31.79
SecondaryChange From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Weeks 28 and 48

Changes from baseline in the 4 types (absenteeism, activity impairment, presenteeism, and Work productivity loss) of WPAI scores at Weeks 28 and 48 were evaluated. The WPAI questionnaire is used to measure productivity loss associated with psoriasis during the past 7 days. It consists of six questions about absence from work because of psoriasis, hours actually worked, reduction in productivity at work attributed to psoriasis and reduction in productivity while performing daily activities. Four separate overall scores were calculated, including absenteeism (work time missed due to health), presenteeism (impairment at work due to health), work productivity loss (overall work impairment due to health), and activity impairment due to health. Each score ranges from 0 to 100 with higher scores indicating greater impairment and less productivity.

Time frame:
Baseline and Weeks 28, 48
Reported as:
Mean · units on a scale
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire Scores at Weeks 28 and 48
units on a scaleGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: Absenteeism-3.0 ± 10.93-2.8 ± 9.12-4.0 ± 8.78-0.1 ± 2.03
Week 28: Activity Impairment-35.1 ± 32.02-33.5 ± 32.19-32.7 ± 29.20-28.1 ± 28.85
Week 28: Presenteeism-26.9 ± 30.83-24.5 ± 34.43-27.1 ± 25.62-18.7 ± 26.85
Week 28: Work Productivity Loss-28.1 ± 31.18-25.1 ± 35.05-28.3 ± 26.61-18.3 ± 26.68
Week 48: Absenteeism-2.0 ± 6.56-2.9 ± 9.37-4.5 ± 9.020.7 ± 2.49
Week 48: Activity Impairment-38.0 ± 30.58-36.8 ± 31.72-36.2 ± 28.44-25.0 ± 30.50
Week 48: Presenteeism-29.3 ± 31.25-30.8 ± 30.97-30.0 ± 29.93-20.4 ± 27.88
Week 48: Work Productivity Loss-29.6 ± 31.88-31.4 ± 31.71-31.5 ± 30.93-19.2 ± 27.84
SecondaryPercentage of Participants Who Achieved American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 Responses at Weeks 4, 8, and 16

ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

Time frame:
Weeks 4, 8, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved American College of Rheumatology (ACR) 20, ACR 50, and ACR 70 Responses at Weeks 4, 8, and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 4: ACR 20 responders027.310.0
Week 4: ACR 50 responders018.20
Week 4: ACR 70 responders09.10
Week 8: ACR 20 responders10.045.520.0
Week 8: ACR 50 responders036.420.0
Week 8: ACR 70 responders018.20
Week 16: ACR 20 responders045.530.0
Week 16: ACR 50 responders018.230.0
Week 16: ACR 70 responders09.130.0
SecondaryPercentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 28, 36, 48, and 52

ACR Response is defined as percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in swollen joint (66 joints) and tender joint (68 joints) counts and percent improvement from baseline of 20%, 50%, and 70% (ACR20, ACR50, and ACR70, respectively) in 3 of following 5 assessments: patient's assessment of pain using VAS (VAS; 0-10, 0=no pain and 10=worst possible pain), patient's global assessment of disease activity by using VAS (scale ranges from 0 to 10, 0=very well and 10=very poor), physician's global assessment of disease activity using VAS (0=no arthritis activity and 10 = extremely active arthritis), patient's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI, defined as a 20-question instrument assessing 8 functional areas;derived HAQ-DI ranges from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area) and serum C-Reactive Protein (CRP).

Time frame:
Weeks 28, 36, 48, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20, ACR 50, and ACR 70 Responses at Weeks 28, 36, 48, and 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: ACR 20 responders36.440.066.70
Week 28: ACR 50 responders27.340.033.30
Week 28: ACR 70 responders18.230.033.30
Week 36: ACR 20 responders45.540.066.750.0
Week 36: ACR 50 responders36.440.066.725.0
Week 36: ACR 70 responders27.340.033.30
Week 48: ACR 20 responders45.530.066.725.0
Week 48: ACR 50 responders45.530.066.725.0
Week 48: ACR 70 responders36.430.066.70
Week 52: ACR 20 responders54.520.066.750.0
Week 52: ACR 50 responders36.420.066.750.0
Week 52: ACR 70 responders27.320.066.70
SecondaryPercent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16

Percent change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.

Time frame:
Weeks 4, 8, and 16
Reported as:
Mean · percent change
Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16
percent changePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 4: Tender joints-7.4 ± 22.2241.1 ± 34.47-8.8 ± 117.56
Week 4: Swollen joints14.1 ± 35.0020.5 ± 39.5022.2 ± 32.77
Week 8: Tender joints-54.6 ± 188.7047.3 ± 39.6150.1 ± 58.06
Week 8: Swollen joints29.5 ± 39.7656.0 ± 42.3350.0 ± 40.82
Week 16: Tender joints-60.2 ± 86.5847.0 ± 40.1222.7 ± 126.76
Week 16: Swollen joints22.7 ± 52.6655.7 ± 46.7179.2 ± 40.05
SecondaryPercent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52

Percent change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.

Time frame:
Weeks 28, 36, 48, and 52
Reported as:
Mean · percent change
Percent Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52
percent changeGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: Tender joints54.9 ± 41.3460.6 ± 46.8033.3 ± 76.38-100.0 ± 81.65
Week 28: Swollen joint66.0 ± 39.1494.4 ± 8.6166.1 ± 29.3643.3 ± 60.28
Week 36: Tender joints69.7 ± 40.6662.1 ± 47.3333.3 ± 76.3825.0 ± 95.74
Week 36: Swollen joint55.2 ± 64.8294.4 ± 13.6184.7 ± 16.8463.3 ± 32.15
Week 48: Tender joints53.9 ± 61.0345.4 ± 73.1450.0 ± 86.6025.0 ± 95.74
Week 48: Swollen joint72.4 ± 42.8480.6 ± 34.0282.8 ± 13.9870.0 ± 26.46
Week 52: Tender joints67.8 ± 47.3132.9 ± 72.4066.7 ± 57.7475.0 ± 50.00
Week 52: Swollen joint84.5 ± 32.7058.3 ± 55.5388.9 ± 19.2586.7 ± 23.09
SecondaryChange From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16

Change from baseline in the tender joints and swollen joints counts at Weeks 4, 8, and 16 was evaluated.

Time frame:
Baseline and Weeks 4, 8, 16
Reported as:
Mean · joints
Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 4, 8, and 16
jointsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 4: Tender joints0.2 ± 0.63-3.8 ± 6.15-1.6 ± 4.74
Week 4: Swollen joints-0.4 ± 0.97-1.2 ± 2.44-0.4 ± 1.58
Week 8: Tender joints0.9 ± 3.38-4.9 ± 9.24-2.6 ± 4.79
Week 8: Swollen joints-1.9 ± 4.68-2.1 ± 2.55-2.2 ± 3.43
Week 16: Tender joints1.3 ± 2.06-3.9 ± 6.32-3.3 ± 5.17
Week 16: Swollen joints-1.3 ± 3.56-2.3 ± 3.41-3.2 ± 4.37
SecondaryChange From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52

Change from baseline in the tender joints and swollen joints counts at Weeks 28, 36, 48 and 52 was evaluated.

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · joints
Change From Baseline in the Tender Joints Count and Swollen Joints Count at Weeks 28, 36, 48, and 52
jointsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28: Tender joints-4.0 ± 6.03-4.1 ± 5.93-1.0 ± 2.001.8 ± 1.71
Week 28: Swollen joint-2.5 ± 2.81-3.4 ± 4.35-9.7 ± 8.02-0.3 ± 0.96
Week 36: Tender joints-3.8 ± 6.23-4.0 ± 5.08-1.0 ± 2.00-1.0 ± 2.16
Week 36: Swollen joint-2.8 ± 3.46-3.6 ± 4.79-11.7 ± 8.62-1.0 ± 0.82
Week 48: Tender joints-3.3 ± 7.18-3.0 ± 4.83-1.3 ± 2.08-1.0 ± 2.16
Week 48: Swollen joint-2.9 ± 3.30-2.5 ± 3.87-11.7 ± 9.29-1.3 ± 1.26
Week 52: Tender joints-7.0 ± 11.19-2.9 ± 4.58-1.7 ± 1.53-1.5 ± 1.73
Week 52: Swollen joint-3.2 ± 3.43-1.5 ± 4.09-12.7 ± 10.26-1.5 ± 1.29
SecondaryPercent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 4, 8, 16

Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 4, 8 and 16 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 millimeter (mm) (no pain) to 100 mm (the worst pain imaginable).

Time frame:
Baseline and Weeks 4, 8, 16
Reported as:
Mean · percent change
Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 4, 8, 16
percent changePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 413.70 ± 23.6983.99 ± 78.91810.32 ± 118.053
Week 82.36 ± 37.86938.19 ± 43.95145.15 ± 55.679
Week 16-0.73 ± 33.06645.51 ± 34.41962.11 ± 41.719
SecondaryPercent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 28, 36, 48, 52

Percent change from baseline in Patient's Assessment of Pain (VAS) among participants who had a diagnosis of PsA at screening at Weeks 28, 36, 48 and 52 was evaluated. Each participant assessed his/her pain associated with joint symptoms on each assessment day using a 100 mm VAS ranging from 0 mm (no pain) to 100 mm (the worst pain imaginable).

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · Percent change
Percent Change From Baseline in Patient's Assessment of Pain (VAS) at Weeks 28, 36, 48, 52
Percent changeGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28-37.67 ± 339.72473.28 ± 28.68751.18 ± 30.41840.96 ± 73.340
Week 36-26.65 ± 273.74568.21 ± 40.53871.92 ± 21.15647.37 ± 46.079
Week 4850.38 ± 74.87457.65 ± 34.86181.36 ± 12.01974.08 ± 14.330
Week 52-30.54 ± 305.27962.09 ± 40.67877.06 ± 23.48761.47 ± 67.467
SecondaryPercent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 4, 8, 16

The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 centimeter \[cm\]) to "very poor" (10 cm).

Time frame:
Baseline and Weeks 4, 8, 16
Reported as:
Mean · percent change
Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 4, 8, 16
percent changePlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 412.55 ± 24.54739.64 ± 38.51458.81 ± 29.281
Week 82.50 ± 34.40244.50 ± 39.32863.10 ± 42.085
Week 16-6.52 ± 28.03721.38 ± 71.54575.70 ± 34.106
SecondaryPercent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 28, 36, 48, and 52

The participant's and physician's global assessments of disease activity were recorded on a VAS. The VAS for the participant's assessment ranges from "very well" (0 cm) to "very poor" (10 cm).

Time frame:
Baseline and Weeks 28, 36, 48, 52
Reported as:
Mean · percent change
Percent Change From Baseline in Patient's Global Assessment of Disease Activity at Weeks 28, 36, 48, and 52
percent changeGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 28-46.83 ± 346.49971.26 ± 35.55245.85 ± 35.01961.23 ± 16.062
Week 36-48.87 ± 341.56375.55 ± 33.99251.95 ± 27.00754.46 ± 27.386
Week 4843.09 ± 109.25458.36 ± 41.13776.02 ± 24.47067.60 ± 20.616
Week 52-20.17 ± 298.48266.00 ± 36.15171.59 ± 34.14069.10 ± 47.796
SecondaryPercentage of Participants Who Achieved Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Weeks 4, 8 and 16

HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).

Time frame:
Weeks 4, 8, and 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Health Assessment Questionnaire-Disability Index (HAQ-DI) Response at Weeks 4, 8 and 16
percentage of participantsPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)
Week 410.036.410.0
Week 820.045.520.0
Week 16054.530.0
SecondaryPercentage of Participants Who Achieved HAQ-DI Response at Weeks 28, 36, 48, 52

HAQ-DI response was defined as change of less than or equal to (\<=) -0.3 from baseline in HAQ-DI score. HAQ-DI is a 20-question instrument that assesses the degree of difficulty a person has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area are scored from 0, indicating no difficulty, to 3, indicating inability to perform a task in that area (that is, lower scores are indicative of better functioning).

Time frame:
Weeks 28, 36, 48, 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved HAQ-DI Response at Weeks 28, 36, 48, 52
percentage of participantsGuselkumab 50 mg (CP)Guselkumab 100 mg (CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Week 2845.530.066.725.0
Week 3654.530.066.70
Week 4845.520.066.725.0
Week 5245.510.066.725.0

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (CP)—2/64 (3.1%)36/64 (56.3%)
Guselkumab 50 mg (CP)—1/65 (1.5%)27/65 (41.5%)
Guselkumab 100 mg (CP)—1/63 (1.6%)26/63 (41.3%)
Guselkumab 50 mg (After CP)—6/63 (9.5%)56/63 (88.9%)
Guselkumab 100 mg (After CP)—6/62 (9.7%)55/62 (88.7%)
Placebo to Guselkumab 50 mg (After CP)—4/26 (15.4%)25/26 (96.2%)
Placebo to Guselkumab 100 mg (After CP)—5/26 (19.2%)26/26 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Guselkumab 50 mg (After CP)Guselkumab 100 mg (After CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
Atrial FibrillationCardiac disorders0/640/650/630/630/621/260/26
Cardiac Failure CongestiveCardiac disorders0/640/650/630/630/621/260/26
CataractEye disorders0/640/650/630/630/620/261/26
Diabetic RetinopathyEye disorders0/640/650/630/630/620/261/26
GlaucomaEye disorders0/640/650/630/630/620/261/26
Macular HoleEye disorders0/640/650/630/630/620/261/26
Vitreous HaemorrhageEye disorders0/640/650/630/630/620/261/26
Gastric PerforationGastrointestinal disorders0/640/650/630/630/621/260/26
Inguinal HerniaGastrointestinal disorders0/640/650/631/630/621/260/26
Large Intestine PolypGastrointestinal disorders0/640/650/630/631/620/261/26
Most frequent other events
Showing 10 of 166
Most frequent other events
EventPlacebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Guselkumab 50 mg (After CP)Guselkumab 100 mg (After CP)Placebo to Guselkumab 50 mg (After CP)Placebo to Guselkumab 100 mg (After CP)
NasopharyngitisInfections and infestations7/6414/658/6338/6331/6214/2614/26
Dental CariesGastrointestinal disorders1/641/652/634/635/626/262/26
BronchitisInfections and infestations1/640/650/632/635/620/266/26
InfluenzaInfections and infestations1/641/650/639/633/625/265/26
CoughRespiratory, thoracic and mediastinal disorders0/640/650/635/632/623/265/26
EczemaSkin and subcutaneous tissue disorders1/640/650/633/637/623/265/26
HypertensionVascular disorders2/642/650/637/636/625/265/26
PsoriasisSkin and subcutaneous tissue disorders11/640/650/630/632/620/261/26
Injection Site ErythemaGeneral disorders1/640/650/635/637/623/264/26
Diabetes MellitusMetabolism and nutrition disorders1/641/650/631/636/620/264/26

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Total
Mean48.3 ± 10.5650.1 ± 12.6647.8 ± 11.0748.8 ± 11.46
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Total
Female10211647
Male544447145
Region of Enrollment
Region of Enrollment(Participants)Placebo (CP)Guselkumab 50 mg (CP)Guselkumab 100 mg (CP)Total
Japan646563192
08

Study locations

27 sites
  • Asahikawa, Japan
  • Chuo, Japan
  • Gifu, Japan
  • Isehara-city,, Japan
  • Izumo, Japan
  • Kanazawa, Japan
  • Kawasaki, Japan
  • Kita-Gun, Japan
  • Kochi, Japan
  • Kurume, Japan
  • Kyoto, Japan
  • Matsumoto, Japan
  • Miyagi, Japan
  • Morioka, Japan
  • Nagoya, Japan
  • Osaka-Sayama, Japan
  • Osaka, Japan
  • Sapporo, Japan
  • Shimotsuke, Japan
  • Shinjuku-ku, Japan
  • Tokushima, Japan
  • Tokyo, Japan
  • Toon, Japan
  • Tsukuba, Japan
  • Tsu, Japan
  • Ube, Japan
  • Yokosuka, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Mar 2016, 14 months.

Results were first posted in May 2020, 4 years 2 months after primary completion.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2014
First posted
Dec 24, 2014
StartActual
Dec 19, 2014
Primary completionActual
Mar 2, 2016
CompletionActual
Feb 8, 2019
Results first posted
May 14, 2020
Last update
May 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02325219
Responsible party
Sponsor
First posted
Dec 24, 2014
Start date
Dec 19, 2014
Primary completion
Mar 2, 2016
Completion
Feb 8, 2019
Results posted
May 14, 2020
Last update
May 22, 2020

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion